-
July 08,2026Highlightll's Girocitinib Received Breakthrough Therapy Designation from CDERead More -
April 27,2026Highlightll Pharma announced positive top-line data from the Phase IIl clinical trial of girocitinib for the treatment of RARead More -
April 02,2026Highlightll Pharma Announces Completion of U.S. Phase I Study of HL-400, a Brain-Penetrant NLRP3 InhibitorRead More -
January 18,2026Highlightll Announces that Girocitinib (TLL-018) Met the Primary Endpoints in the Interim Analysis of Its Phase Ⅲ Trial in Chronic Spontaneous Urticaria (CSU)Read More -
January 11,2026Highlightll Announces Completion of the SAD Portion in the PhaseⅠ Study of Its Brain-Penetrant NLRP3 Inhibitor HL-400Read More
